IN THE SPECIFICATION

Par. [0054], please amend as follows:

For example, in the case of MMP 2 and MMP 9, octapeptides (P4-P'4) have been identified, which octapeptides simulate the cleavage sequence of the collagen chain and are cleaved particularly efficiently by MMP 2 and 9:

Peptide

$P_4\ P_3\ P_2\ P_1\ P'_1\ P'_2\ P'_3\ P'_4$

Gly-Pro-**Leu**-Gly-Ile-Ala-Gly-Gln (SEQ ID NO:1)

Gly-Pro-Gln-Gly-Ile-**Trp**-Gly-Gln (SEQ ID NO:2)

Paragraph [0055], please amend as follwos:

Furthermore, substrate-specific dipeptides having the sequence –Arg-Arg- (SEQ ID NO: 3), -Phe-Lys- (SEQ ID NO: 4), Gly-Phe-Leu-Gly (SEQ ID NO: 5), Gly-Phe-Ala-Leu (SEQ ID NO: 6), and Ala-Leu-Ala-Leu (SEQ ID NO: 7) are known in the case of cathepsin B (Werle, B., Ebert, E., Klein, W., Spiess, E. (1995), *Biol. Chem. Hoppe-Seyler* 376, 157-164; Ulricht, B., Spiess, E., Schwartz-Albiez, R., Ebert, W. (1995), *Biol. Chem. Hoppe-Seyler* 376, 404-414.

Paragraph [0056], please amend as follows:

The peptide sequence which contains the expected peptide cleavage site which is relevant for the target enzyme can also be constructed such that the expected peptide cleavage site is repeated several times, for example by means of:

-Gly-Pro-**Leu**-Gly-Ile-Ala-Gly-Gln-Gly-Pro-**Leu**-Gly-Ile-Ala-Gly-Gln (SEQ ID NO: 8)

or

Phe-Lys-Phe-Lys-Phe-Lys-Phe-Lys-Phe-Lys-Phe-Lys (SEQ ID NO:9)

Paragraph [0057] please amend as follows:

or it is possible to integrate a repetitive peptide sequence which increases the distance between the protein-binding molecule and the relevant expected peptide cleavage site, as, for example, by means of:

-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Phe-Lys-Phe-Lys- (SEQ ID NO: 10)

Paragraph [0085], please amend as follows:

In this preparation, the maleimidoglycine-derivatized octapeptide Gln-Gly-Ala-Ile-Gly-Leu-Pro-Gly (SEQ ID NO: 11) 1 (Mr 848, prepared by Bachem AG, Switzerland using solid-phase synthesis) is reacted with doxorubicin in accordance with the following protocol:

Paragraph [088], please amend as follows:

The peptide sequence Gln-Gly-Ala-Ile-Gly-Leu-Pro-Gly (SEQ ID NO: 11) is recognized by the matrix metalloprotease MMP9 and cleaved between isoleucine and glycine. This was demonstrated by the following experiment: 200 µl of a 100 µM solution of the albumin conjugate of 2 having the following structure (abbreviated to HSA-2):



HSA = human serum albumin

which was prepared by the method described in German Patent Application A19926475.9, dated 10 Jun. 1999, was incubated, at 37° for 30 minutes, with trypsin/aprotinin-activated MMP9 (2 mU, from Calbiochem, Germany). The release of DOXO-Gln-Gly-Ala-Ile after this time is depicted in the following chromatograms. The figure shows the chromatogram of HSA-2 at t=0 (separation by means of HPLC exclusion chromatography using a Biosil 250 SEC column supplied by Biorad, detection at λ=495 nm) and after having been incubated with activated MMP9 for 30 minutes (see Figs. 5A and 5B).